Alector announces appointment of sara kenkare-mitra, ph.d., as president and head of research and development

South san francisco, calif., dec. 15, 2021 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of sara kenkare-mitra, ph.d., as president and head of research and development. in this newly created role, dr. kenkare-mitra will lead all aspects of the company's immuno-neurology and oncology r&d efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. dr. kenkare-mitra will report to arnon rosenthal, ph.d., chief executive officer of alector.
ALEC Ratings Summary
ALEC Quant Ranking